Actoxumab 产品活性：Actoxumab 是一种抗艰难梭菌毒素 A (C. difficile toxin A) 的抗毒素抗体，能够靶向并破坏 TcdA。Actoxumab 能够防止可以防止肠道壁的损伤和与艰难梭菌有关的炎症反应。Actoxumab 与靶向 TcdB 的 Bezlotoxumab (HY-P9929) 表现出良好的协同作用。 产品来源： https://www.medchemexpress.cn/actoxumab.html 研究领域：Others 作用靶点：Others In Vitro: Actoxumab (10 mg/kg WT or N297Q mutant (N297Q) actoxumab-bezlotoxumab; 2 h plus 24 h) significantly inhibits cell rounding activity in Vero cells under 2 ng/mL TcdA treatment. In Vivo: Actoxumab (0.1-10 mg/kg or 50 mg/kg; i.p.; single dose) shows protective effect in multiple murine models of clostridium difficile infection (CDI), including systemic and local (gut) toxin challenge models, as well as primary and recurrent models of infection in mice. Actoxumab shows a synergy with Bezlotoxumab, and (combination dosage of 3, 30, 300 μg/mouse; i.p.; single dose) prevents both epithelial damage and inflammatory disease. 相关产品：Digitonin | 5-Ph-IAA | FLAG peptide | 3X FLAG peptide | TCEP hydrochloride | Monocrotaline | Tocofersolan | Pronase E (Activity ≥ 7000 U/g) | DPPH | DNase I, Bovine pancreas | NMDI14 | O-Propargyl-Puromycin | Human IgG1 kappa, Isotype Control | Phytohemagglutinin | Hyaluronidase | Biotinyl tyramide | MYLS22 | Pertussis Toxin | N,N-Dimethylformamide | Kifunensine | OVA Peptide (323-339) | L-Tryptophan | 6-Aminonicotinamide | Lauryl maltose neopentyl glycol | Alkyne-phenol | Potassium oxonate | OVA Peptide(257-264) TFA | CHAPS | Teriparatide 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。